查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1420998

药物和基因输送系统市场 - 2023-2031 年全球产业分析、规模、份额、数量、成长、趋势和预测

Drug and Gene Delivery Systems Market - Global Industry Analysis, Size, Share, Volume, Growth, Trends, and Forecast 2023-2031
出版日期: | 出版商: Transparency Market Research | 英文 334 Pages | 商品交期: 2-10个工作天内

价格

药物和基因递送系统市场 - 报告范围

TMR 关于全球药物和基因递送系统市场的报告研究了过去以及当前的成长趋势和机会，以获得 2023 年至 2031 年预测期内市场指标的宝贵见解。该报告提供了全球药物的收入2017-2031 年期间的基因传递系统市场，以2023 年为基准年，2031 年为预测年。报告中也提供了2023年至2031年全球药物和基因递送系统市场的年复合成长率（CAGR %）。

该报告是经过广泛研究后编写的。初级研究涉及大部分研究工作，其中分析师对关键意见领袖、行业领导者和舆论製造者进行了采访。二次研究涉及参考主要参与者的产品文献、年度报告、新闻稿和相关文件，以了解药物和基因递送系统市场。

市场概况
2023年市场价值 34 亿美元
2031 年市场价值 78 亿美元
CAGR 10%

该报告深入研究了全球药物和基因递送系统市场的竞争格局。全球药物和基因递送系统市场的主要参与者已经确定，并且每个参与者都根据各种属性进行了分析。公司概况、财务状况、最新发展和 SWOT 是本报告中介绍的全球药物和基因递送系统市场参与者的属性。

目录

第一章：前言

第 2 章：假设与研究方法

第 3 章：执行摘要：全球市场

第 4 章：市场概览

  • 介绍
  • 概述
  • 市场动态
  • 2017-2031年全球市场分析与预测

第 5 章：关键见解

  • 管道分析
  • 密钥交付系统/品牌分析
  • 主要併购
  • COVID-19 大流行对该行业的影响

第 6 章：全球市场分析与预测：按交付系统

  • 简介与定义
  • 主要发现/进展
  • 市场价值预测：按交付系统，2017-2031
    • 药物输送系统
      • 子宫内植入物
      • 前药植入物
      • 聚合物药物递送
      • 标靶给药
    • 基因传递系统
      • 病毒基因传递
        • 腺病毒载体
        • 慢病毒载体
        • 逆转录病毒载体
        • 腺相关病毒载体
        • 仙台病毒载体
        • 单纯疱疹病毒载体
        • 其他的
      • 非病毒基因传递
        • 天然有机化合物
        • 物理方法
        • 化学方法
      • 组合式混合动力系统
  • 市场吸引力分析：按交付系统

第 7 章：全球市场分析与预测：按给药途径

  • 简介与定义
  • 主要发现/进展
  • 市场价值预测：依给药途径，2017-2031
    • 口服
    • 可注射
    • 吸入
    • 透皮
    • 眼睛
    • 鼻腔
    • 专题
  • 市场吸引力分析：按给药途径

第 8 章：全球市场分析与预测：按应用分类

  • 简介与定义
  • 主要发现/进展
  • 市场价值预测：依应用分类，2017-2031
    • 传染性疾病
    • 肿瘤学
    • 眼科
    • 泌尿科
    • 糖尿病
    • 中枢神经系统
    • 其他的
  • 市场吸引力分析：按应用

第 9 章：全球市场分析与预测：按地区

  • 主要发现
  • 市场价值预测：按地区，2017-2031
    • 北美洲
    • 欧洲
    • 亚太地区
    • 拉丁美洲
    • 中东和非洲
  • 市场吸引力分析：按地区

第 10 章：北美市场分析与预测

第 11 章：欧洲市场分析与预测

第 12 章：亚太市场分析与预测

第 13 章：拉丁美洲市场分析与预测

第 14 章：中东和非洲市场分析与预测

第15章：竞争格局

  • 市场参与者 - 竞争矩阵（依公司层级和规模）
  • 市占率分析：依公司划分（2022 年）
  • 公司简介
    • Novartis AG
    • Amgen Inc.
    • Oxford BioMedica plc.
    • SIBIONO
    • Shanghai Sunway Biotech Co., Ltd.
    • F. Hoffmann-La Roche Ltd.
    • Pfizer, Inc.
    • Bayer AG
    • Johnson & Johnson Services, Inc.
    • Becton, Dickinson and Company
    • AstraZeneca plc
    • Baxter International, Inc.
    • Boston Scientific Corporation
    • GenVivo, Inc.
Product Code: TMRGL26135

Drug and Gene Delivery Systems Market - Scope of Report

TMR's report on the global drug and gene delivery systems market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global drug and gene delivery systems market for the period 2017-2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global drug and gene delivery systems market from 2023 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the drug and gene delivery systems market.

Market Snapshot
Market Value in 2023US$ 3.4 Bn
Market Value in 2031US$ 7.8 Bn
CAGR10%

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global drug and gene delivery systems market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global drug and gene delivery systems market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global drug and gene delivery systems market.

The report delves into the competitive landscape of the global drug and gene delivery systems market. Key players operating in the global drug and gene delivery systems market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global drug and gene delivery systems market profiled in this report.

Key Questions Answered in Global drug and gene delivery systems Market Report:

  • What is the sales/revenue generated by drug and gene delivery systems across all regions during the forecast period?
  • What are the opportunities in the global drug and gene delivery systems market?
  • What are the major drivers, restraints, opportunities, and threats in the market?
  • Which regional market is set to expand at the fastest CAGR during the forecast period?
  • Which segment is expected to generate the highest revenue globally in 2031?
  • Which segment is projected to expand at the highest CAGR during the forecast period?
  • What are the market positions of different companies operating in the global market?

Drug and Gene Delivery Systems Market - Research Objectives and Research Approach

The comprehensive report on the global drug and gene delivery systems market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global drug and gene delivery systems market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global drug and gene delivery systems market.

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Drug and Gene Delivery Systems Market

4. Market Overview

  • 4.1. Introduction
    • 4.1.1. Delivery System Definition
    • 4.1.2. Industry Evolution/Developments
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Global Drug and Gene Delivery Systems Market Analysis and Forecast, 2017-2031

5. Key Insights

  • 5.1. Pipeline Analysis
  • 5.2. Key Delivery System/Brand Analysis
  • 5.3. Key Mergers & Acquisitions
  • 5.4. COVID-19 Pandemic Impact on Industry

6. Global Drug and Gene Delivery Systems Market Analysis and Forecast, by Delivery System

  • 6.1. Introduction & Definition
  • 6.2. Key Findings/Developments
  • 6.3. Market Value Forecast, by Delivery System, 2017-2031
    • 6.3.1. Drug Delivery Systems
      • 6.3.1.1. Intrauterine Implants
      • 6.3.1.2. Prodrug Implants
      • 6.3.1.3. Polymeric Drug Delivery
      • 6.3.1.4. Targeted Drug Delivery
    • 6.3.2. Gene Delivery Systems
      • 6.3.2.1. Viral Gene Delivery
        • 6.3.2.1.1. Adenovirus Vector
        • 6.3.2.1.2. Lentivirus Vector
        • 6.3.2.1.3. Retrovirus Vector
        • 6.3.2.1.4. Adeno-associated Virus Vector
        • 6.3.2.1.5. Sendai Virus Vector
        • 6.3.2.1.6. Herpes Simplex Virus Vector
        • 6.3.2.1.7. Others
      • 6.3.2.2. Non-viral Gene Delivery
        • 6.3.2.2.1. Natural Organic Compounds
        • 6.3.2.2.2. Physical Methods
        • 6.3.2.2.3. Chemical Methods
      • 6.3.2.3. Combined Hybrid System
  • 6.4. Market Attractiveness Analysis, by Delivery System

7. Global Drug and Gene Delivery Systems Market Analysis and Forecast, by Route of Administration

  • 7.1. Introduction & Definition
  • 7.2. Key Findings/Developments
  • 7.3. Market Value Forecast, by Route of Administration, 2017-2031
    • 7.3.1. Oral
    • 7.3.2. Injectable
    • 7.3.3. Inhalation
    • 7.3.4. Transdermal
    • 7.3.5. Ocular
    • 7.3.6. Nasal
    • 7.3.7. Topical
  • 7.4. Market Attractiveness Analysis, by Route of Administration

8. Global Drug and Gene Delivery Systems Market Analysis and Forecast, by Application

  • 8.1. Introduction & Definition
  • 8.2. Key Findings/Developments
  • 8.3. Market Value Forecast, by Application, 2017-2031
    • 8.3.1. Infectious Diseases
    • 8.3.2. Oncology
    • 8.3.3. Ophthalmology
    • 8.3.4. Urology
    • 8.3.5. Diabetes
    • 8.3.6. CNS
    • 8.3.7. Others
  • 8.4. Market Attractiveness Analysis, by Application

9. Global Drug and Gene Delivery Systems Market Analysis and Forecast, by Region

  • 9.1. Key Findings
  • 9.2. Market Value Forecast, by Region, 2017-2031
    • 9.2.1. North America
    • 9.2.2. Europe
    • 9.2.3. Asia Pacific
    • 9.2.4. Latin America
    • 9.2.5. Middle East & Africa
  • 9.3. Market Attractiveness Analysis, by Region

10. North America Drug and Gene Delivery Systems Market Analysis and Forecast

  • 10.1. Introduction
  • 10.2. Key Findings
  • 10.3. Market Value Forecast, by Delivery System, 2017-2031
    • 10.3.1. Drug Delivery Systems
      • 10.3.1.1. Intrauterine Implants
      • 10.3.1.2. Prodrug Implants
      • 10.3.1.3. Polymeric Drug Delivery
      • 10.3.1.4. Targeted Drug Delivery
    • 10.3.2. Gene Delivery Systems
      • 10.3.2.1. Viral Gene Delivery
        • 10.3.2.1.1. Adenovirus Vector
        • 10.3.2.1.2. Lentivirus Vector
        • 10.3.2.1.3. Retrovirus Vector
        • 10.3.2.1.4. Adeno-associated Virus Vector
        • 10.3.2.1.5. Sendai Virus Vector
        • 10.3.2.1.6. Herpes Simplex Virus Vector
        • 10.3.2.1.7. Others
      • 10.3.2.2. Non-viral Gene Delivery
        • 10.3.2.2.1. Natural Organic Compounds
        • 10.3.2.2.2. Physical Methods
        • 10.3.2.2.3. Chemical Methods
      • 10.3.2.3. Combined Hybrid System
  • 10.4. Market Value Forecast, by Route of Administration, 2017-2031
    • 10.4.1. Oral
    • 10.4.2. Injectable
    • 10.4.3. Inhalation
    • 10.4.4. Transdermal
    • 10.4.5. Ocular
    • 10.4.6. Nasal
    • 10.4.7. Topical
  • 10.5. Market Value Forecast, by Application, 2017-2031
    • 10.5.1. Infectious Diseases
    • 10.5.2. Oncology
    • 10.5.3. Ophthalmology
    • 10.5.4. Urology
    • 10.5.5. Diabetes
    • 10.5.6. CNS
    • 10.5.7. Others
  • 10.6. Market Value Forecast, by Country, 2017-2031
    • 10.6.1. U.S.
    • 10.6.2. Canada
  • 10.7. Market Attractiveness Analysis
    • 10.7.1. By Delivery System
    • 10.7.2. By Route of Administration
    • 10.7.3. By Application
    • 10.7.4. By Country

11. Europe Drug and Gene Delivery Systems Market Analysis and Forecast

  • 11.1. Introduction
  • 11.2. Key Findings
  • 11.3. Market Value Forecast, by Delivery System, 2017-2031
    • 11.3.1. Drug Delivery Systems
      • 11.3.1.1. Intrauterine Implants
      • 11.3.1.2. Prodrug Implants
      • 11.3.1.3. Polymeric Drug Delivery
      • 11.3.1.4. Targeted Drug Delivery
    • 11.3.2. Gene Delivery Systems
      • 11.3.2.1. Viral Gene Delivery
        • 11.3.2.1.1. Adenovirus Vector
        • 11.3.2.1.2. Lentivirus Vector
        • 11.3.2.1.3. Retrovirus Vector
        • 11.3.2.1.4. Adeno-associated Virus Vector
        • 11.3.2.1.5. Sendai Virus Vector
        • 11.3.2.1.6. Herpes Simplex Virus Vector
        • 11.3.2.1.7. Others
      • 11.3.2.2. Non-viral Gene Delivery
        • 11.3.2.2.1. Natural Organic Compounds
        • 11.3.2.2.2. Physical Methods
        • 11.3.2.2.3. Chemical Methods
      • 11.3.2.3. Combined Hybrid System
  • 11.4. Market Value Forecast, by Route of Administration, 2017-2031
    • 11.4.1. Oral
    • 11.4.2. Injectable
    • 11.4.3. Inhalation
    • 11.4.4. Transdermal
    • 11.4.5. Ocular
    • 11.4.6. Nasal
    • 11.4.7. Topical
  • 11.5. Market Value Forecast, by Application, 2017-2031
    • 11.5.1. Infectious Diseases
    • 11.5.2. Oncology
    • 11.5.3. Ophthalmology
    • 11.5.4. Urology
    • 11.5.5. Diabetes
    • 11.5.6. CNS
    • 11.5.7. Others
  • 11.6. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 11.6.1. Germany
    • 11.6.2. U.K.
    • 11.6.3. France
    • 11.6.4. Italy
    • 11.6.5. Spain
    • 11.6.6. Rest of Europe
  • 11.7. Market Attractiveness Analysis
    • 11.7.1. By Delivery System
    • 11.7.2. By Route of Administration
    • 11.7.3. By Application
    • 11.7.4. By Country/Sub-region

12. Asia Pacific Drug and Gene Delivery Systems Market Analysis and Forecast

  • 12.1. Introduction
  • 12.2. Key Findings
  • 12.3. Market Value Forecast, by Delivery System, 2017-2031
    • 12.3.1. Drug Delivery Systems
      • 12.3.1.1. Intrauterine Implants
      • 12.3.1.2. Prodrug Implants
      • 12.3.1.3. Polymeric Drug Delivery
      • 12.3.1.4. Targeted Drug Delivery
    • 12.3.2. Gene Delivery Systems
      • 12.3.2.1. Viral Gene Delivery
        • 12.3.2.1.1. Adenovirus Vector
        • 12.3.2.1.2. Lentivirus Vector
        • 12.3.2.1.3. Retrovirus Vector
        • 12.3.2.1.4. Adeno-associated Virus Vector
        • 12.3.2.1.5. Sendai Virus Vector
        • 12.3.2.1.6. Herpes Simplex Virus Vector
        • 12.3.2.1.7. Others
      • 12.3.2.2. Non-viral Gene Delivery
        • 12.3.2.2.1. Natural Organic Compounds
        • 12.3.2.2.2. Physical Methods
        • 12.3.2.2.3. Chemical Methods
      • 12.3.2.3. Combined Hybrid System
  • 12.4. Market Value Forecast, by Route of Administration, 2017-2031
    • 12.4.1. Oral
    • 12.4.2. Injectable
    • 12.4.3. Inhalation
    • 12.4.4. Transdermal
    • 12.4.5. Ocular
    • 12.4.6. Nasal
    • 12.4.7. Topical
  • 12.5. Market Value Forecast, by Application, 2017-2031
    • 12.5.1. Infectious Diseases
    • 12.5.2. Oncology
    • 12.5.3. Ophthalmology
    • 12.5.4. Urology
    • 12.5.5. Diabetes
    • 12.5.6. CNS
    • 12.5.7. Others
  • 12.6. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 12.6.1. China
    • 12.6.2. Japan
    • 12.6.3. India
    • 12.6.4. Australia & New Zealand
    • 12.6.5. Rest of Asia Pacific
  • 12.7. Market Attractiveness Analysis
    • 12.7.1. By Delivery System
    • 12.7.2. By Route of Administration
    • 12.7.3. By Application
    • 12.7.4. By Country/Sub-region

13. Latin America Drug and Gene Delivery Systems Market Analysis and Forecast

  • 13.1. Introduction
  • 13.2. Key Findings
  • 13.3. Market Value Forecast, by Delivery System, 2017-2031
    • 13.3.1. Drug Delivery Systems
      • 13.3.1.1. Intrauterine Implants
      • 13.3.1.2. Prodrug Implants
      • 13.3.1.3. Polymeric Drug Delivery
      • 13.3.1.4. Targeted Drug Delivery
    • 13.3.2. Gene Delivery Systems
      • 13.3.2.1. Viral Gene Delivery
        • 13.3.2.1.1. Adenovirus Vector
        • 13.3.2.1.2. Lentivirus Vector
        • 13.3.2.1.3. Retrovirus Vector
        • 13.3.2.1.4. Adeno-associated Virus Vector
        • 13.3.2.1.5. Sendai Virus Vector
        • 13.3.2.1.6. Herpes Simplex Virus Vector
        • 13.3.2.1.7. Others
      • 13.3.2.2. Non-viral Gene Delivery
        • 13.3.2.2.1. Natural Organic Compounds
        • 13.3.2.2.2. Physical Methods
        • 13.3.2.2.3. Chemical Methods
      • 13.3.2.3. Combined Hybrid System
  • 13.4. Market Value Forecast, by Route of Administration, 2017-2031
    • 13.4.1. Oral
    • 13.4.2. Injectable
    • 13.4.3. Inhalation
    • 13.4.4. Transdermal
    • 13.4.5. Ocular
    • 13.4.6. Nasal
    • 13.4.7. Topical
  • 13.5. Market Value Forecast, by Application, 2017-2031
    • 13.5.1. Infectious Diseases
    • 13.5.2. Oncology
    • 13.5.3. Ophthalmology
    • 13.5.4. Urology
    • 13.5.5. Diabetes
    • 13.5.6. CNS
    • 13.5.7. Others
  • 13.6. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 13.6.1. Brazil
    • 13.6.2. Mexico
    • 13.6.3. Rest of Latin America
  • 13.7. Market Attractiveness Analysis
    • 13.7.1. By Delivery System
    • 13.7.2. By Route of Administration
    • 13.7.3. By Application
    • 13.7.4. By Country/Sub-region

14. Middle East & Africa Drug and Gene Delivery Systems Market Analysis and Forecast

  • 14.1. Introduction
  • 14.2. Key Findings
  • 14.3. Market Value Forecast, by Delivery System, 2017-2031
    • 14.3.1. Drug Delivery Systems
      • 14.3.1.1. Intrauterine Implants
      • 14.3.1.2. Prodrug Implants
      • 14.3.1.3. Polymeric Drug Delivery
      • 14.3.1.4. Targeted Drug Delivery
    • 14.3.2. Gene Delivery Systems
      • 14.3.2.1. Viral Gene Delivery
        • 14.3.2.1.1. Adenovirus Vector
        • 14.3.2.1.2. Lentivirus Vector
        • 14.3.2.1.3. Retrovirus Vector
        • 14.3.2.1.4. Adeno-associated Virus Vector
        • 14.3.2.1.5. Sendai Virus Vector
        • 14.3.2.1.6. Herpes Simplex Virus Vector
        • 14.3.2.1.7. Others
      • 14.3.2.2. Non-viral Gene Delivery
        • 14.3.2.2.1. Natural Organic Compounds
        • 14.3.2.2.2. Physical Methods
        • 14.3.2.2.3. Chemical Methods
      • 14.3.2.3. Combined Hybrid System
  • 14.4. Market Value Forecast, by Route of Administration, 2017-2031
    • 14.4.1. Oral
    • 14.4.2. Injectable
    • 14.4.3. Inhalation
    • 14.4.4. Transdermal
    • 14.4.5. Ocular
    • 14.4.6. Nasal
    • 14.4.7. Topical
  • 14.5. Market Value Forecast, by Application, 2017-2031
    • 14.5.1. Infectious Diseases
    • 14.5.2. Oncology
    • 14.5.3. Ophthalmology
    • 14.5.4. Urology
    • 14.5.5. Diabetes
    • 14.5.6. CNS
    • 14.5.7. Others
  • 14.6. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 14.6.1. GCC Countries
    • 14.6.2. South Africa
    • 14.6.3. Rest of Middle East & Africa
  • 14.7. Market Attractiveness Analysis
    • 14.7.1. By Delivery System
    • 14.7.2. By Route of Administration
    • 14.7.3. By Application
    • 14.7.4. By Country/Sub-region

15. Competition Landscape

  • 15.1. Market Player - Competitive Matrix (by Tier and Size of Companies)
  • 15.2. Market Share Analysis, by Company (2022)
  • 15.3. Company Profiles
    • 15.3.1. Novartis AG
      • 15.3.1.1. Company Overview
      • 15.3.1.2. Delivery System Portfolio
      • 15.3.1.3. SWOT Analysis
      • 15.3.1.4. Financial Overview
      • 15.3.1.5. Strategic Overview
    • 15.3.2. Amgen Inc.
      • 15.3.2.1. Company Overview
      • 15.3.2.2. Delivery System Portfolio
      • 15.3.2.3. SWOT Analysis
      • 15.3.2.4. Financial Overview
      • 15.3.2.5. Strategic Overview
    • 15.3.3. Oxford BioMedica plc.
      • 15.3.3.1. Company Overview
      • 15.3.3.2. Delivery System Portfolio
      • 15.3.3.3. SWOT Analysis
      • 15.3.3.4. Financial Overview
      • 15.3.3.5. Strategic Overview
    • 15.3.4. SIBIONO
      • 15.3.4.1. Company Overview
      • 15.3.4.2. Delivery System Portfolio
      • 15.3.4.3. SWOT Analysis
      • 15.3.4.4. Financial Overview
      • 15.3.4.5. Strategic Overview
    • 15.3.5. Shanghai Sunway Biotech Co., Ltd.
      • 15.3.5.1. Company Overview
      • 15.3.5.2. Delivery System Portfolio
      • 15.3.5.3. SWOT Analysis
      • 15.3.5.4. Financial Overview
      • 15.3.5.5. Strategic Overview
    • 15.3.6. F. Hoffmann-La Roche Ltd.
      • 15.3.6.1. Company Overview
      • 15.3.6.2. Delivery System Portfolio
      • 15.3.6.3. SWOT Analysis
      • 15.3.6.4. Financial Overview
      • 15.3.6.5. Strategic Overview
    • 15.3.7. Pfizer, Inc.
      • 15.3.7.1. Company Overview
      • 15.3.7.2. Delivery System Portfolio
      • 15.3.7.3. SWOT Analysis
      • 15.3.7.4. Financial Overview
      • 15.3.7.5. Strategic Overview
    • 15.3.8. Bayer AG
      • 15.3.8.1. Company Overview
      • 15.3.8.2. Delivery System Portfolio
      • 15.3.8.3. SWOT Analysis
      • 15.3.8.4. Financial Overview
      • 15.3.8.5. Strategic Overview
    • 15.3.9. Johnson & Johnson Services, Inc.
      • 15.3.9.1. Company Overview
      • 15.3.9.2. Delivery System Portfolio
      • 15.3.9.3. SWOT Analysis
      • 15.3.9.4. Financial Overview
      • 15.3.9.5. Strategic Overview
    • 15.3.10. Becton, Dickinson and Company
      • 15.3.10.1. Company Overview
      • 15.3.10.2. Delivery System Portfolio
      • 15.3.10.3. SWOT Analysis
      • 15.3.10.4. Financial Overview
      • 15.3.10.5. Strategic Overview
    • 15.3.11. AstraZeneca plc
      • 15.3.11.1. Company Overview
      • 15.3.11.2. Delivery System Portfolio
      • 15.3.11.3. SWOT Analysis
      • 15.3.11.4. Financial Overview
      • 15.3.11.5. Strategic Overview
    • 15.3.12. Baxter International, Inc.
      • 15.3.12.1. Company Overview
      • 15.3.12.2. Delivery System Portfolio
      • 15.3.12.3. SWOT Analysis
      • 15.3.12.4. Financial Overview
      • 15.3.12.5. Strategic Overview
    • 15.3.13. Boston Scientific Corporation
      • 15.3.13.1. Company Overview
      • 15.3.13.2. Delivery System Portfolio
      • 15.3.13.3. SWOT Analysis
      • 15.3.13.4. Financial Overview
      • 15.3.13.5. Strategic Overview
    • 15.3.14. GenVivo, Inc.
      • 15.3.14.1. Company Overview
      • 15.3.14.2. Delivery System Portfolio
      • 15.3.14.3. SWOT Analysis
      • 15.3.14.4. Financial Overview
      • 15.3.14.5. Strategic Overview

List of Tables

  • Table 01: Global Drug and Gene Delivery Systems Market Size (US$ Mn) Forecast, by Delivery System, 2017-2031
  • Table 02: Global Drug and Gene Delivery Systems Market Size (US$ Mn) Forecast, by Route of Administration, 2017-2031
  • Table 03: Global Drug and Gene Delivery Systems Market Size (US$ Mn) Forecast, by Application, 2017-2031
  • Table 04: Global Drug and Gene Delivery Systems Market Size (US$ Mn) Forecast, by Region, 2017-2031
  • Table 05: North America Drug and Gene Delivery Systems Market Size (US$ Mn) Forecast, by Country, 2017-2031
  • Table 06: North America Drug and Gene Delivery Systems Market Size (US$ Mn) Forecast, by Delivery System, 2017-2031
  • Table 07: North America Drug and Gene Delivery Systems Market Size (US$ Mn) Forecast, by Route of Administration, 2017-2031
  • Table 08: North America Drug and Gene Delivery Systems Market Size (US$ Mn) Forecast, by Application, 2017-2031
  • Table 09: Europe Drug and Gene Delivery Systems Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 10: Europe Drug and Gene Delivery Systems Market Size (US$ Mn) Forecast, by Delivery System, 2017-2031
  • Table 11: Europe Drug and Gene Delivery Systems Market Size (US$ Mn) Forecast, by Route of Administration, 2017-2031
  • Table 12: Europe Drug and Gene Delivery Systems Market Size (US$ Mn) Forecast, by Application, 2017-2031
  • Table 13: Asia Pacific Drug and Gene Delivery Systems Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 14: Asia Pacific Drug and Gene Delivery Systems Market Size (US$ Mn) Forecast, by Delivery System, 2017-2031
  • Table 15: Asia Pacific Drug and Gene Delivery Systems Market Size (US$ Mn) Forecast, by Route of Administration, 2017-2031
  • Table 16: Asia Pacific Drug and Gene Delivery Systems Market Size (US$ Mn) Forecast, by Application, 2017-2031
  • Table 17: Latin America Drug and Gene Delivery Systems Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 18: Latin America Drug and Gene Delivery Systems Market Size (US$ Mn) Forecast, by Delivery System, 2017-2031
  • Table 19: Latin America Drug and Gene Delivery Systems Market Size (US$ Mn) Forecast, by Route of Administration, 2017-2031
  • Table 20: Latin America Drug and Gene Delivery Systems Market Size (US$ Mn) Forecast, by Application, 2017-2031
  • Table 21: Middle East & Africa Drug and Gene Delivery Systems Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 22: Middle East & Africa Drug and Gene Delivery Systems Market Size (US$ Mn) Forecast, by Delivery System, 2017-2031
  • Table 23: Middle East & Africa Drug and Gene Delivery Systems Market Size (US$ Mn) Forecast, by Route of Administration, 2017-2031
  • Table 24: Middle East & Africa Drug and Gene Delivery Systems Market Size (US$ Mn) Forecast, by Application, 2017-2031

List of Figures

  • Figure 01: Global Drug and Gene Delivery Systems Market Size (US$ Mn) and Distribution (%), by Region, 2022 and 2031
  • Figure 02: Global Drug and Gene Delivery Systems Market Revenue (US$ Mn), by Delivery System, 2022
  • Figure 03: Global Drug and Gene Delivery Systems Market Value Share, by Delivery System, 2022
  • Figure 04: Global Drug and Gene Delivery Systems Market Revenue (US$ Mn), by Route of Administration, 2022
  • Figure 05: Global Drug and Gene Delivery Systems Market Value Share, by Route of Administration, 2022
  • Figure 06: Global Drug and Gene Delivery Systems Market Revenue (US$ Mn), by Application, 2022
  • Figure 07: Global Drug and Gene Delivery Systems Market Value Share, by Application, 2022
  • Figure 08: Global Drug and Gene Delivery Systems Market Value Share, by Region, 2022
  • Figure 09: Global Drug and Gene Delivery Systems Market Value (US$ Mn) Forecast, 2023-2031
  • Figure 10: Global Drug and Gene Delivery Systems Market Value Share Analysis, by Delivery System, 2022 and 2031
  • Figure 11: Global Drug and Gene Delivery Systems Market Attractiveness Analysis, by Delivery System, 2023-2031
  • Figure 12: Global Drug and Gene Delivery Systems Market Value Share Analysis, by Route of Administration, 2022 and 2031
  • Figure 13: Global Drug and Gene Delivery Systems Market Attractiveness Analysis, by Route of Administration, 2023-2031
  • Figure 14: Global Drug and Gene Delivery Systems Market Value Share Analysis, by Application, 2022 and 2031
  • Figure 15: Global Drug and Gene Delivery Systems Market Attractiveness Analysis, by Application, 2022-2031
  • Figure 16: Global Drug and Gene Delivery Systems Market Value Share Analysis, by Region, 2022 and 2031
  • Figure 17: Global Drug and Gene Delivery Systems Market Attractiveness Analysis, by Region, 2022-2031
  • Figure 18: North America Drug and Gene Delivery Systems Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017-2031
  • Figure 19: North America Drug and Gene Delivery Systems Market Attractiveness Analysis, by Country, 2023-2031
  • Figure 20: North America Drug and Gene Delivery Systems Market Value Share Analysis, by Country, 2022 and 2031
  • Figure 21: North America Drug and Gene Delivery Systems Market Value Share Analysis, by Delivery System, 2022 and 2031
  • Figure 22: North America Drug and Gene Delivery Systems Market Value Share Analysis, by Route of Administration, 2022 and 2031
  • Figure 23: North America Drug and Gene Delivery Systems Market Value Share Analysis, by Application, 2022 and 2031
  • Figure 24: North America Drug and Gene Delivery Systems Market Attractiveness Analysis, by Delivery System, 2023-2031
  • Figure 25: North America Drug and Gene Delivery Systems Market Attractiveness Analysis, by Route of Administration, 2023-2031
  • Figure 26:North America Drug and Gene Delivery Systems Market Attractiveness Analysis, by Application, 2023-2031
  • Figure 27: Europe Drug and Gene Delivery Systems Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017-2031
  • Figure 28: Europe Drug and Gene Delivery Systems Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 29: Europe Drug and Gene Delivery Systems Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
  • Figure 30: Europe Drug and Gene Delivery Systems Market Value Share Analysis, by Delivery System, 2022 and 2031
  • Figure 31: Europe Drug and Gene Delivery Systems Market Value Share Analysis, by Route of Administration, 2022 and 2031
  • Figure 32: Europe Drug and Gene Delivery Systems Market Value Share Analysis, by Application, 2022 and 2031
  • Figure 33: Europe Drug and Gene Delivery Systems Market Attractiveness Analysis, by Delivery System, 2023-2031
  • Figure 34: Europe Drug and Gene Delivery Systems Market Attractiveness Analysis, by Route of Administration, 2023-2031
  • Figure 35: Europe Drug and Gene Delivery Systems Market Attractiveness Analysis, by Application, 2023-2031
  • Figure 36: Asia Pacific Drug and Gene Delivery Systems Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017-2031
  • Figure 37: Asia Pacific Drug and Gene Delivery Systems Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 38: Asia Pacific Drug and Gene Delivery Systems Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
  • Figure 39: Asia Pacific Drug and Gene Delivery Systems Market Value Share Analysis, by Delivery System, 2022 and 2031
  • Figure 40: Asia Pacific Drug and Gene Delivery Systems Market Value Share Analysis, by Route of Administration, 2022 and 2031
  • Figure 41: Asia Pacific Drug and Gene Delivery Systems Market Value Share Analysis, by Application, 2022 and 2031
  • Figure 42: Asia Pacific Drug and Gene Delivery Systems Market Attractiveness Analysis, by Delivery System, 2023-2031
  • Figure 43: Asia Pacific Drug and Gene Delivery Systems Market Attractiveness Analysis, by Route of Administration, 2023-2031
  • Figure 44: Asia Pacific Drug and Gene Delivery Systems Market Attractiveness Analysis, by Application, 2023-2031
  • Figure 45: Latin America Drug and Gene Delivery Systems Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017-2031
  • Figure 46: Latin America Drug and Gene Delivery Systems Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 47: Latin America Drug and Gene Delivery Systems Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
  • Figure 48: Latin America Drug and Gene Delivery Systems Market Value Share Analysis, by Delivery System, 2022 and 2031
  • Figure 49: Latin America Drug and Gene Delivery Systems Market Value Share Analysis, by Route of Administration, 2022 and 2031
  • Figure 50: Latin America Drug and Gene Delivery Systems Market Value Share Analysis, by Application, 2022 and 2031
  • Figure 51: Latin America Drug and Gene Delivery Systems Market Attractiveness Analysis, by Delivery System, 2023-2031
  • Figure 52: Latin America Drug and Gene Delivery Systems Market Attractiveness Analysis, by Route of Administration, 2023-2031
  • Figure 53: Latin America Drug and Gene Delivery Systems Market Attractiveness Analysis, by Application, 2023-2031
  • Figure 54: Middle East & Africa Drug and Gene Delivery Systems Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2017-2031
  • Figure 55: Middle East & Africa Drug and Gene Delivery Systems Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 56: Middle East & Africa Drug and Gene Delivery Systems Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
  • Figure 57: Middle East & Africa Drug and Gene Delivery Systems Market Value Share Analysis, by Delivery System, 2022 and 2031
  • Figure 58: Middle East & Africa Drug and Gene Delivery Systems Market Value Share Analysis, by Route of Administration, 2022 and 2031
  • Figure 59: Middle East & Africa Drug and Gene Delivery Systems Market Value Share Analysis, by Application, 2022 and 2031
  • Figure 60: Middle East & Africa Drug and Gene Delivery Systems Market Attractiveness Analysis, by Delivery System, 2023-2031
  • Figure 61: Middle East & Africa Drug and Gene Delivery Systems Market Attractiveness Analysis, by Route of Administration, 2023-2031
  • Figure 62: Middle East & Africa Drug and Gene Delivery Systems Market Attractiveness Analysis, by Application, 2023-2031